Spero Therapeutics (SPRO) closed at $1.00 on November 12, 2026, down 2.0% from the previous close, on volume of 310,824 shares (30-day average 415,662).
Data as of November 12, 2026.
Spero Therapeutics GAAP EPS of -$0.76 misses by $0.62
Seeking Alpha News (Thu, 12-Nov 4:50 PM ET)
Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update
Globe Newswire (Thu, 12-Nov 4:05 PM ET)
Spero Therapeutics Appoints William Ho to Board
TipRanks (Tue, 10-Nov 6:19 PM ET)
Spero Therapeutics Appoints William Ho, M.D., Ph.D., to its Board of Directors
Globe Newswire (Tue, 10-Nov 8:00 AM ET)
Alphabet maintains massive SpaceX bet, initiates $548M Qualcomm stake
Seeking Alpha News (Mon, 9-Nov 12:47 AM ET)
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
Spero Therapeutics to Present at Investor Conferences in November
Globe Newswire (Mon, 2-Nov 4:05 PM ET)
Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
Globe Newswire (Mon, 26-Oct 8:00 AM ET)
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
Globe Newswire (Thu, 15-Oct 4:05 PM ET)
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 2-Oct 4:05 PM ET)
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Spero Therapeutics trades on the NASDAQ stock market under the symbol SPRO.
As of November 13, 2026, SPRO stock price was flat at $1.00 with 345,695 million shares trading.
SPRO has a beta of 1.31, meaning it tends to be more sensitive to market movements. SPRO has a correlation of 0.08 to the broad based SPY ETF.
SPRO has a market cap of $58.23 million. This is considered a Micro Cap stock.
In the last 3 years, SPRO traded as high as $3.22 and as low as $.51.
The top ETF exchange traded funds that SPRO belongs to (by Net Assets): VTI, VXF, IWC, QQQS, PRFZ.
SPRO has underperformed the market in the last year with a price return of -62.4% while the SPY ETF gained +11.5%. SPRO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.0% and -9.9%, respectively, while the SPY returned -2.1% and -2.0%, respectively.
SPRO support price is $.96 and resistance is $1.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRO shares will trade within this expected range on the day.
